Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc., a clinical-stage biotechnology…
Month: February 2021
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
– Product revenues of $476 million for full year 2020, $110 million for the fourth…
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type…
Inventiva to participate at several investor conferences in March 2021
Daix (France), February 24, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical…
Segra Enters Agreement Making BioAgronomics Group’s Premium Cannabis Cultivar Portfolio Available to Licensed Producers Across Canada and Select International Markets
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) — Segra International Corp., an AgTech firm…
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) — Pan-Biome Pharmaceuticals, Inc, a Vancouver based…
LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid®…
22nd Century Group Provides Business Update Letter from CEO
Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis WILLIAMSVILLE, N.Y., Feb….
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS)…
AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer Prof. Casper…
Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy
Phase 1b trial demonstrates that the company’s lead precision medicine asset is safe and well…
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model The…
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company…
Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data
Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review MORRISVILLE, N.C….
Medexus Schedules Third Quarter Fiscal 2021 Conference Call
TORONTO and CHICAGO and MONTREAL, Feb. 24, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the…
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events…
Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company…
Kane Biotech Announces New Chairman
WINNIPEG, Manitoba, Feb. 24, 2021 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage…